{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:41:28Z","timestamp":1793403688740,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160501"],"award-info":[{"award-number":["82160501"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018571","name":"Specific Research Project of Guangxi for Research Bases and Talents","doi-asserted-by":"publisher","award":["AD22035042"],"award-info":[{"award-number":["AD22035042"]}],"id":[{"id":"10.13039\/501100018571","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018571","name":"Specific Research Project of Guangxi for Research Bases and Talents","doi-asserted-by":"publisher","award":["AB23026002"],"award-info":[{"award-number":["AB23026002"]}],"id":[{"id":"10.13039\/501100018571","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060512"],"award-info":[{"award-number":["82060512"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060460"],"award-info":[{"award-number":["82060460"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303316"],"award-info":[{"award-number":["82303316"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","award":["2019GXNSFAA245097"],"award-info":[{"award-number":["2019GXNSFAA245097"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-024-05685-8","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T08:02:35Z","timestamp":1728028955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Multi-omics analysis unveils the predictive value of IGF2BP3\/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in muscle-invasive bladder cancer"],"prefix":"10.1186","volume":"22","author":[{"given":"Yaobang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuyue","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zezu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanliang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"5685_CR1","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","volume":"5","author":"N Lobo","year":"2022","unstructured":"Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP, Gupta S, Smith AB, Williams SB, Lotan Y. Epidemiology, screening, and prevention of bladder cancer. Eur Urol Oncol. 2022;5:628\u201339.","journal-title":"Eur Urol Oncol"},{"key":"5685_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","volume":"20","author":"LMC van Hoogstraten","year":"2023","unstructured":"van Hoogstraten LMC, Vrieling A, van der Heijden AG, Kogevinas M, Richters A, Kiemeney LA. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol. 2023;20:287\u2013304.","journal-title":"Nat Rev Clin Oncol"},{"key":"5685_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"5685_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81:75\u201394.","journal-title":"Eur Urol"},{"key":"5685_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, Theodorescu D. Bladder cancer. Nat Rev Dis Primers. 2023;9:58.","journal-title":"Nat Rev Dis Primers"},{"key":"5685_CR6","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA. 2020;324:1980\u201391.","journal-title":"JAMA"},{"key":"5685_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/nrurol.2017.82","volume":"14","author":"N Lobo","year":"2017","unstructured":"Lobo N, Mount C, Omar K, Nair R, Thurairaja R, Khan MS. Landmarks in the treatment of muscle-invasive bladder cancer. Nat Rev Urol. 2017;14:565\u201374.","journal-title":"Nat Rev Urol"},{"key":"5685_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558\u201362.","journal-title":"Nature"},{"key":"5685_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847\u201356.","journal-title":"Mol Cancer Ther"},{"key":"5685_CR10","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.annonc.2020.07.002","volume":"31","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Solit DB, Chan TA, Kurzrock R. The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) \u226510: a decision centered on empowering patients and their physicians. Ann Oncol. 2020;31:1115\u20138.","journal-title":"Ann Oncol"},{"key":"5685_CR11","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019;25:1706\u201314.","journal-title":"Nat Med"},{"key":"5685_CR12","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xun Z, Ma K, Liang S, Li X, Zhou S, Sun L, Liu Y, Du Y, Guo X, et al. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol. 2023;78:770\u201382.","journal-title":"J Hepatol"},{"key":"5685_CR13","doi-asserted-by":"publisher","first-page":"106862","DOI":"10.1016\/j.isci.2023.106862","volume":"26","author":"HC Zhao","year":"2023","unstructured":"Zhao HC, Chen CZ, Tian YZ, Song HQ, Wang XX, Li YJ, He JF, Zhao HL. CD168(+) macrophages promote hepatocellular carcinoma tumor stemness and progression through TOP2A\/\u03b2-catenin\/YAP1 axis. iScience. 2023;26:106862.","journal-title":"iScience"},{"key":"5685_CR14","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1097\/HEP.0000000000000600","volume":"79","author":"E Maestri","year":"2024","unstructured":"Maestri E, Kedei N, Khatib S, Forgues M, Ylaya K, Hewitt SM, Wang L, Chaisaingmongkol J, Ruchirawat M, Ma L, Wang XW. Spatial proximity of tumor-immune interactions predicts patient outcome in hepatocellular carcinoma. Hepatology. 2024;79:768\u201379.","journal-title":"Hepatology"},{"key":"5685_CR15","doi-asserted-by":"publisher","first-page":"7533","DOI":"10.1038\/s41467-022-35291-5","volume":"13","author":"L Ma","year":"2022","unstructured":"Ma L, Heinrich S, Wang L, Keggenhoff FL, Khatib S, Forgues M, Kelly M, Hewitt SM, Saif A, Hernandez JM, et al. Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer. Nat Commun. 2022;13:7533.","journal-title":"Nat Commun"},{"key":"5685_CR16","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-16-1417","volume":"23","author":"BA Inman","year":"2017","unstructured":"Inman BA, Longo TA, Ramalingam S, Harrison MR. Atezolizumab: a PD-L1-blocking antibody for bladder cancer. Clin Cancer Res. 2017;23:1886\u201390.","journal-title":"Clin Cancer Res"},{"key":"5685_CR17","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375:1767\u201378.","journal-title":"N Engl J Med"},{"key":"5685_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56\u201361.","journal-title":"Science"},{"key":"5685_CR19","first-page":"10","volume":"2019","author":"Y Wu","year":"2022","unstructured":"Wu Y, Chen W, Xu ZP, Gu W. PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol. 2022;2019:10.","journal-title":"Front Immunol"},{"key":"5685_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2174\/157488810793351640","volume":"5","author":"MN Tran","year":"2010","unstructured":"Tran MN, Goodwin Jinesh G, McConkey DJ, Kamat AM. Bladder cancer stem cells. Curr Stem Cell Res Ther. 2010;5:387\u201395.","journal-title":"Curr Stem Cell Res Ther"},{"key":"5685_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/path.4086","volume":"229","author":"P Grosse-Gehling","year":"2013","unstructured":"Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D, Kunz-Schughart LA. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol. 2013;229:355\u201378.","journal-title":"J Pathol"},{"key":"5685_CR22","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/ijc.32505","volume":"146","author":"T Namekawa","year":"2020","unstructured":"Namekawa T, Ikeda K, Horie-Inoue K, Suzuki T, Okamoto K, Ichikawa T, Yano A, Kawakami S, Inoue S. ALDH1A1 in patient-derived bladder cancer spheroids activates retinoic acid signaling leading to TUBB3 overexpression and tumor progression. Int J Cancer. 2020;146:1099\u2013113.","journal-title":"Int J Cancer"},{"key":"5685_CR23","doi-asserted-by":"publisher","first-page":"4626","DOI":"10.1038\/s41388-018-0292-2","volume":"37","author":"G Maurizi","year":"2018","unstructured":"Maurizi G, Verma N, Gadi A, Mansukhani A, Basilico C. Sox2 is required for tumor development and cancer cell proliferation in osteosarcoma. Oncogene. 2018;37:4626\u201332.","journal-title":"Oncogene"},{"key":"5685_CR24","doi-asserted-by":"publisher","first-page":"188887","DOI":"10.1016\/j.bbcan.2023.188887","volume":"1878","author":"P Verma","year":"2023","unstructured":"Verma P, Shukla N, Kumari S, Ansari MS, Gautam NK, Patel GK. Cancer stem cell in prostate cancer progression, metastasis and therapy resistance. Biochim Biophys Acta Rev Cancer. 2023;1878:188887.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"5685_CR25","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1002\/stem.97","volume":"27","author":"B Gonz\u00e1lez","year":"2009","unstructured":"Gonz\u00e1lez B, Denzel S, Mack B, Conrad M, Gires O. EpCAM is involved in maintenance of the murine embryonic stem cell phenotype. Stem Cells. 2009;27:1782\u201391.","journal-title":"Stem Cells"},{"key":"5685_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.stem.2015.02.015","volume":"16","author":"V Plaks","year":"2015","unstructured":"Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell. 2015;16:225\u201338.","journal-title":"Cell Stem Cell"},{"key":"5685_CR27","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.1038\/s41467-021-25103-7","volume":"12","author":"KH Gouin 3rd","year":"2021","unstructured":"Gouin KH 3rd, Ing N, Plummer JT, Rosser CJ, Ben Cheikh B, Oh C, Chen SS, Chan KS, Furuya H, Tourtellotte WG, et al. An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer. Nat Commun. 2021;12:4906.","journal-title":"Nat Commun"},{"key":"5685_CR28","doi-asserted-by":"publisher","unstructured":"Minoli M, Cantore T, Hanhart D, Kiener M, Fedrizzi T, La Manna F, Karkampouna S, Chouvardas P, Genitsch V, Rodriguez-Calero A, Comp\u00e9rat E, Klima I, Gasperini P, Kiss B, Seiler R, Demichelis F, Thalmann GN, Kruithof-de Julio M (2023) Bladder cancer organoids as a functional system to model different disease stages and therapy response. Abst Nat Commun. https:\/\/doi.org\/10.1038\/s41467-023-37696-2.","DOI":"10.1038\/s41467-023-37696-2"},{"key":"5685_CR29","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","volume":"26","author":"DA Braun","year":"2020","unstructured":"Braun DA, Hou Y, Bakouny Z, Ficial M, Sant\u2019 Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26:909\u201318.","journal-title":"Nat Med"},{"key":"5685_CR30","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1038\/s41467-024-48310-4","volume":"15","author":"J Kang","year":"2024","unstructured":"Kang J, Lee JH, Cha H, An J, Kwon J, Lee S, Kim S, Baykan MY, Kim SY, An D, et al. Systematic dissection of tumor-normal single-cell ecosystems across a thousand tumors of 30 cancer types. Nat Commun. 2024;15:4067.","journal-title":"Nat Commun"},{"key":"5685_CR31","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019;25:1916\u201327.","journal-title":"Nat Med"},{"key":"5685_CR32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2021.02.015","volume":"39","author":"K Bi","year":"2021","unstructured":"Bi K, He MX, Bakouny Z, Kanodia A, Napolitano S, Wu J, Grimaldi G, Braun DA, Cuoco MS, Mayorga A, et al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell. 2021;39:649-661.e645.","journal-title":"Cancer Cell"},{"key":"5685_CR33","doi-asserted-by":"publisher","first-page":"5440","DOI":"10.3390\/cancers13215440","volume":"13","author":"C Feng","year":"2021","unstructured":"Feng C, Wang X, Tao Y, Xie Y, Lai Z, Li Z, Hu J, Tang S, Pan L, He L, et al. Single-cell proteomic analysis dissects the complexity of tumor microenvironment in muscle invasive bladder cancer. Cancers. 2021;13:5440.","journal-title":"Cancers"},{"key":"5685_CR34","doi-asserted-by":"publisher","first-page":"1057302","DOI":"10.3389\/fgene.2022.1057302","volume":"13","author":"Y Tao","year":"2022","unstructured":"Tao Y, Li X, Zhang Y, He L, Lu Q, Wang Y, Pan L, Wang Z, Feng C, Xie Y, et al. TP53-related signature for predicting prognosis and tumor microenvironment characteristics in bladder cancer: a multi-omics study. Front Genet. 2022;13:1057302.","journal-title":"Front Genet"},{"key":"5685_CR35","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.1038\/s41467-020-18916-5","volume":"11","author":"Z Chen","year":"2020","unstructured":"Chen Z, Zhou L, Liu L, Hou Y, Xiong M, Yang Y, Hu J, Chen K. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat Commun. 2020;11:5077.","journal-title":"Nat Commun"},{"key":"5685_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308438","volume":"11","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Jin W, Qian K, Ju L, Wang G, Wu K, Cao R, Chang L, Xu Z, Luo J, et al. Integrative single cell atlas revealed intratumoral heterogeneity generation from an adaptive epigenetic cell state in human bladder urothelial carcinoma. Adv Sci. 2024;11: e2308438.","journal-title":"Adv Sci"},{"key":"5685_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-021-01447-y","volume":"21","author":"W Wan","year":"2022","unstructured":"Wan W, Ao X, Chen Q, Yu Y, Ao L, Xing W, Guo W, Wu X, Pu C, Hu X, et al. METTL3\/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N(6)-methyladenosine modification of PD-L1 mRNA in breast cancer. Mol Cancer. 2022;21:60.","journal-title":"Mol Cancer"},{"key":"5685_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-021-01398-4","volume":"20","author":"Z Liu","year":"2021","unstructured":"Liu Z, Wang T, She Y, Wu K, Gu S, Li L, Dong C, Chen C, Zhou Y. N(6)-methyladenosine-modified circIGF2BP3 inhibits CD8(+) T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer. Mol Cancer. 2021;20:105.","journal-title":"Mol Cancer"},{"key":"5685_CR39","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","volume":"12","author":"SV Lindskrog","year":"2021","unstructured":"Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtr\u00f6der K, Jensen JB, Strandgaard T, Nordentoft I, Christensen E, et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021;12:2301.","journal-title":"Nat Commun"},{"key":"5685_CR40","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000515305","volume":"10","author":"CL Hsu","year":"2021","unstructured":"Hsu CL, Ou DL, Bai LY, Chen CW, Lin L, Huang SF, Cheng AL, Jeng YM, Hsu C. Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma. Liver Cancer. 2021;10:346\u201359.","journal-title":"Liver Cancer"},{"key":"5685_CR41","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40364-023-00499-0","volume":"11","author":"TY Zhu","year":"2023","unstructured":"Zhu TY, Hong LL, Ling ZQ. Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential. Biomark Res. 2023;11:62.","journal-title":"Biomark Res"},{"key":"5685_CR42","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reyni\u00e8s A, Allory Y, Sj\u00f6dahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77:420\u201333.","journal-title":"Eur Urol"},{"key":"5685_CR43","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.1158\/1078-0432.CCR-20-4796","volume":"27","author":"H Wang","year":"2021","unstructured":"Wang H, Mei Y, Luo C, Huang Q, Wang Z, Lu GM, Qin L, Sun Z, Huang CW, Yang ZW, et al. Single-cell analyses reveal mechanisms of cancer stem cell maintenance and epithelial-mesenchymal transition in recurrent bladder cancer. Clin Cancer Res. 2021;27:6265\u201378.","journal-title":"Clin Cancer Res"},{"key":"5685_CR44","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.3390\/ijms24054760","volume":"24","author":"L Ma","year":"2023","unstructured":"Ma L, Chen H, Yang W, Ji Z. Crosstalk between mesenchymal stem cells and cancer stem cells reveals a novel stemness-related signature to predict prognosis and immunotherapy responses for bladder cancer patients. Int J Mol Sci. 2023;24:4760.","journal-title":"Int J Mol Sci"},{"key":"5685_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2174\/1574888X08666131113123051","volume":"9","author":"G Goodwin Jinesh","year":"2014","unstructured":"Goodwin Jinesh G, Willis DL, Kamat AM. Bladder cancer stem cells: biological and therapeutic perspectives. Curr Stem Cell Res Ther. 2014;9:89\u2013101.","journal-title":"Curr Stem Cell Res Ther"},{"key":"5685_CR46","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1038\/s41388-018-0664-7","volume":"38","author":"J Zhu","year":"2019","unstructured":"Zhu J, Huang G, Hua X, Li Y, Yan H, Che X, Tian Z, Liufu H, Huang C, Li J, et al. CD44s is a crucial ATG7 downstream regulator for stem-like property, invasion, and lung metastasis of human bladder cancer (BC) cells. Oncogene. 2019;38:3301\u201315.","journal-title":"Oncogene"},{"key":"5685_CR47","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3892\/mco.2012.29","volume":"1","author":"P Huang","year":"2013","unstructured":"Huang P, Watanabe M, Kaku H, Ueki H, Noguchi H, Sugimoto M, Hirata T, Yamada H, Takei K, Zheng S, et al. Cancer stem cell-like characteristics of a CD133(+) subpopulation in the J82 human bladder cancer cell line. Mol Clin Oncol. 2013;1:180\u20134.","journal-title":"Mol Clin Oncol"},{"key":"5685_CR48","doi-asserted-by":"publisher","first-page":"8261","DOI":"10.1038\/s41598-020-65006-z","volume":"10","author":"YF Chiu","year":"2020","unstructured":"Chiu YF, Wu CC, Kuo MH, Miao CC, Zheng MY, Chen PY, Lin SC, Chang JL, Wang YH, Chou YT. Critical role of SOX2-IGF2 signaling in aggressiveness of bladder cancer. Sci Rep. 2020;10:8261.","journal-title":"Sci Rep"},{"key":"5685_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12943-020-1143-7","volume":"19","author":"Y Zhan","year":"2020","unstructured":"Zhan Y, Chen Z, He S, Gong Y, He A, Li Y, Zhang L, Zhang X, Fang D, Li X, Zhou L. Long non-coding RNA SOX2OT promotes the stemness phenotype of bladder cancer cells by modulating SOX2. Mol Cancer. 2020;19:25.","journal-title":"Mol Cancer"},{"key":"5685_CR50","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","volume":"1","author":"C Ginestier","year":"2007","unstructured":"Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555\u201367.","journal-title":"Cell Stem Cell"},{"key":"5685_CR51","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1158\/0008-5472.CAN-15-0361","volume":"76","author":"T Ishiguro","year":"2016","unstructured":"Ishiguro T, Sato A, Ohata H, Ikarashi Y, Takahashi RU, Ochiya T, Yoshida M, Tsuda H, Onda T, Kato T, et al. Establishment and characterization of an in vitro model of ovarian cancer stem-like cells with an enhanced proliferative capacity. Cancer Res. 2016;76:150\u201360.","journal-title":"Cancer Res"},{"key":"5685_CR52","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1158\/0008-5472.CAN-08-4418","volume":"69","author":"EH Huang","year":"2009","unstructured":"Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009;69:3382\u20139.","journal-title":"Cancer Res"},{"key":"5685_CR53","doi-asserted-by":"publisher","first-page":"M111.010744","DOI":"10.1074\/mcp.M111.010744","volume":"11","author":"J He","year":"2012","unstructured":"He J, Liu Y, Zhu T, Zhu J, Dimeco F, Vescovi AL, Heth JA, Muraszko KM, Fan X, Lubman DM. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Mol Cell Proteom. 2012;11:M111.010744.","journal-title":"Mol Cell Proteom"},{"key":"5685_CR54","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0168-8278(98)80065-2","volume":"29","author":"T Roskams","year":"1998","unstructured":"Roskams T, De Vos R, Van Eyken P, Myazaki H, Van Damme B, Desmet V. Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J Hepatol. 1998;29:455\u201363.","journal-title":"J Hepatol"},{"key":"5685_CR55","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1053\/j.gastro.2010.08.053","volume":"139","author":"TG Levin","year":"2010","unstructured":"Levin TG, Powell AE, Davies PS, Silk AD, Dismuke AD, Anderson EC, Swain JR, Wong MH. Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. Gastroenterology. 2010;139:2072-2082.e2075.","journal-title":"Gastroenterology"},{"key":"5685_CR56","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/nature06196","volume":"449","author":"N Barker","year":"2007","unstructured":"Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, Clevers H. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature. 2007;449:1003\u20137.","journal-title":"Nature"},{"key":"5685_CR57","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13046-018-0864-6","volume":"37","author":"J Zhang","year":"2018","unstructured":"Zhang J, Cai H, Sun L, Zhan P, Chen M, Zhang F, Ran Y, Wan J. LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt\/\u03b2-catenin pathway and predicts poor survival of glioma patients. J Exp Clin Cancer Res. 2018;37:225.","journal-title":"J Exp Clin Cancer Res"},{"key":"5685_CR58","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jhep.2009.10.026","volume":"52","author":"B Terris","year":"2010","unstructured":"Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol. 2010;52:280\u20131.","journal-title":"J Hepatol"},{"key":"5685_CR59","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41401-018-0050-6","volume":"40","author":"XT Qi","year":"2019","unstructured":"Qi XT, Li YL, Zhang YQ, Xu T, Lu B, Fang L, Gao JQ, Yu LS, Zhu DF, Yang B, et al. KLF4 functions as an oncogene in promoting cancer stem cell-like characteristics in osteosarcoma cells. Acta Pharmacol Sin. 2019;40:546\u201355.","journal-title":"Acta Pharmacol Sin"},{"key":"5685_CR60","doi-asserted-by":"publisher","first-page":"E80","DOI":"10.1210\/jc.2011-2187","volume":"97","author":"M Garcia-Lavandeira","year":"2012","unstructured":"Garcia-Lavandeira M, Saez C, Diaz-Rodriguez E, Perez-Romero S, Senra A, Dieguez C, Japon MA, Alvarez CV. Craniopharyngiomas express embryonic stem cell markers (SOX2, OCT4, KLF4, and SOX9) as pituitary stem cells but do not coexpress RET\/GFRA3 receptors. J Clin Endocrinol Metab. 2012;97:E80-87.","journal-title":"J Clin Endocrinol Metab"},{"key":"5685_CR61","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13046-020-01714-8","volume":"39","author":"Z Yang","year":"2020","unstructured":"Yang Z, Wang T, Wu D, Min Z, Tan J, Yu B. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer. J Exp Clin Cancer Res. 2020;39:203.","journal-title":"J Exp Clin Cancer Res"},{"key":"5685_CR62","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/s12967-023-04235-y","volume":"21","author":"F Yang","year":"2023","unstructured":"Yang F, Ma Q, Huang B, Wang X, Pan X, Yu T, Ran L, Jiang S, Li H, Chen Y, et al. CircNFATC3 promotes the proliferation of gastric cancer through binding to IGF2BP3 and restricting its ubiquitination to enhance CCND1 mRNA stability. J Transl Med. 2023;21:402.","journal-title":"J Transl Med"},{"key":"5685_CR63","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41419-023-06099-y","volume":"14","author":"LJ Chen","year":"2023","unstructured":"Chen LJ, Liu HY, Xiao ZY, Qiu T, Zhang D, Zhang LJ, Han FY, Chen GJ, Xu XM, Zhu JH, et al. IGF2BP3 promotes the progression of colorectal cancer and mediates cetuximab resistance by stabilizing EGFR mRNA in an m(6)A-dependent manner. Cell Death Dis. 2023;14:581.","journal-title":"Cell Death Dis"},{"key":"5685_CR64","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1158\/0008-5472.CAN-23-0557","volume":"83","author":"J Tang","year":"2023","unstructured":"Tang J, Wang S, Weng M, Guo Q, Ren L, He Y, Cui Z, Cong M, Qin M, Yu J, et al. The IGF2BP3-COPS7B axis facilitates mRNA translation to drive colorectal cancer progression. Cancer Res. 2023;83:3593\u2013610.","journal-title":"Cancer Res"},{"key":"5685_CR65","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S1470-2045(06)70732-X","volume":"7","author":"Z Jiang","year":"2006","unstructured":"Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Hsieh CC, Li C, Chen W, Duan HO, McDougal S, Wu CL. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 2006;7:556\u201364.","journal-title":"Lancet Oncol"},{"key":"5685_CR66","first-page":"31","volume":"27","author":"NO Ozdemir","year":"2011","unstructured":"Ozdemir NO, T\u00fcrk NS, D\u00fczcan E. IMP3 expression in urothelial carcinomas of the urinary bladder. Turk Patoloji Derg. 2011;27:31\u20137.","journal-title":"Turk Patoloji Derg"},{"key":"5685_CR67","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1158\/1078-0432.CCR-07-2039","volume":"14","author":"L Sitnikova","year":"2008","unstructured":"Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K, Mohanty S, Rock KL, Jiang Z. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res. 2008;14:1701\u20136.","journal-title":"Clin Cancer Res"},{"key":"5685_CR68","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1038\/s41388-023-02865-6","volume":"42","author":"B Chen","year":"2023","unstructured":"Chen B, Huang R, Xia T, Wang C, Xiao X, Lu S, Chen X, Ouyang Y, Deng X, Miao J, et al. The m6A reader IGF2BP3 preserves NOTCH3 mRNA stability to sustain Notch3 signaling and promote tumor metastasis in nasopharyngeal carcinoma. Oncogene. 2023;42:3564\u201374.","journal-title":"Oncogene"},{"key":"5685_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2023.5500","volume":"62","author":"W Fu","year":"2023","unstructured":"Fu W, Lei X, Lu Q, Zhang J, Guo J, Zhao J, Tong X, Hu X. UBE2K regulated by IGF2BP3 promotes cell proliferation and stemness in pancreatic ductal adenocarcinoma. Int J Oncol. 2023;62:1.","journal-title":"Int J Oncol"},{"key":"5685_CR70","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrc.2017.96","volume":"18","author":"B Ogretmen","year":"2018","unstructured":"Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer. 2018;18:33\u201350.","journal-title":"Nat Rev Cancer"},{"key":"5685_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2415","volume":"33","author":"L Zhang","year":"2023","unstructured":"Zhang L, Liu J, Xiao E, Han Q, Wang L. Sphingosine-1-phosphate related signalling pathways manipulating virus replication. Rev Med Virol. 2023;33: e2415.","journal-title":"Rev Med Virol"},{"key":"5685_CR72","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.canlet.2008.11.025","volume":"276","author":"MH Li","year":"2009","unstructured":"Li MH, Sanchez T, Yamase H, Hla T, Oo ML, Pappalardo A, Lynch KR, Lin CY, Ferrer F. S1P\/S1P1 signaling stimulates cell migration and invasion in Wilms tumor. Cancer Lett. 2009;276:171\u20139.","journal-title":"Cancer Lett"},{"key":"5685_CR73","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1158\/1541-7786.MCR-17-0681","volume":"16","author":"JC Cheng","year":"2018","unstructured":"Cheng JC, Wang EY, Yi Y, Thakur A, Tsai SH, Hoodless PA. S1P stimulates proliferation by upregulating CTGF expression through S1PR2-mediated YAP activation. Mol Cancer Res. 2018;16:1543\u201355.","journal-title":"Mol Cancer Res"},{"key":"5685_CR74","doi-asserted-by":"publisher","first-page":"154197","DOI":"10.1016\/j.prp.2022.154197","volume":"240","author":"S Zeng","year":"2022","unstructured":"Zeng S, Liang Y, Hu H, Wang F, Liang L. Endothelial cell-derived S1P promotes migration and stemness by binding with GPR63 in colorectal cancer. Pathol Res Pract. 2022;240:154197.","journal-title":"Pathol Res Pract"},{"key":"5685_CR75","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1038\/ncomms5806","volume":"5","author":"N Hirata","year":"2014","unstructured":"Hirata N, Yamada S, Shoda T, Kurihara M, Sekino Y, Kanda Y. Sphingosine-1-phosphate promotes expansion of cancer stem cells via S1PR3 by a ligand-independent Notch activation. Nat Commun. 2014;5:4806.","journal-title":"Nat Commun"},{"key":"5685_CR76","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.eururo.2018.09.022","volume":"75","author":"N van Dijk","year":"2019","unstructured":"van Dijk N, Funt SA, Blank CU, Powles T, Rosenberg JE, van der Heijden MS. The cancer immunogram as a framework for personalized immunotherapy in urothelial cancer. Eur Urol. 2019;75:435\u201344.","journal-title":"Eur Urol"},{"key":"5685_CR77","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463\u20139.","journal-title":"Science"},{"key":"5685_CR78","first-page":"264","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71:264\u201379.","journal-title":"CA Cancer J Clin"}],"updated-by":[{"DOI":"10.1186\/s12967-025-06717-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000}}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05685-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05685-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05685-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:37:30Z","timestamp":1757119050000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05685-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5685"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05685-8","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12967-025-06717-7","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"26 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12967-025-06717-7","URL":"https:\/\/doi.org\/10.1186\/s12967-025-06717-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Medical Ethics Committee approved the collection and the experimentation of Guangxi Medical University. This study was approved by the ethics committee of the First Affiliated Hospital of Guangxi Medical University (2024-E444-01, Supplementary Table\u00a02). Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"900"}}